1. Home
  2. LEN vs NTRA Comparison

LEN vs NTRA Comparison

Compare LEN & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lennar Corporation

LEN

Lennar Corporation

HOLD

Current Price

$121.38

Market Cap

31.0B

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$237.70

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEN
NTRA
Founded
1954
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.0B
27.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
LEN
NTRA
Price
$121.38
$237.70
Analyst Decision
Hold
Strong Buy
Analyst Count
15
15
Target Price
$111.46
$249.53
AVG Volume (30 Days)
4.2M
1.1M
Earning Date
12-16-2025
02-26-2026
Dividend Yield
1.62%
N/A
EPS Growth
N/A
N/A
EPS
7.98
N/A
Revenue
$34,186,934,000.00
$2,116,676,000.00
Revenue This Year
$0.28
$33.18
Revenue Next Year
N/A
$16.81
P/E Ratio
$15.45
N/A
Revenue Growth
N/A
38.17
52 Week Low
$98.42
$125.38
52 Week High
$144.24
$256.36

Technical Indicators

Market Signals
Indicator
LEN
NTRA
Relative Strength Index (RSI) 61.70 55.14
Support Level $102.80 $226.12
Resistance Level $123.75 $243.47
Average True Range (ATR) 3.30 8.19
MACD 2.64 -0.52
Stochastic Oscillator 88.79 41.80

Price Performance

Historical Comparison
LEN
NTRA

About LEN Lennar Corporation

Lennar is one of the largest public homebuilders in the United States. The company's homebuilding operations target first-time, move-up, active adult, and luxury homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily and single-family for-rent construction and has invested in numerous housing-related technology startups.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: